Review ArticlesLimited-Stage Hodgkin Lymphoma Minimizing ToxicityStraus, David J. MD*†Author Information *From the Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; and †Weill Cornell Medicine, New York, NY. Conflicts of Interest and Source of Funding: The Lymphoma Foundation, Rob and Karen Schneider and The Louis Schneider and Harry Davis Memorial Trust, The Adam R. Spector Foundation, The David R. and Patricia D. Atkinson Foundation, and Mr. and Mrs. Ernest Dicker. Reprints: David J. Straus, MD, Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave Box 330 New York, NY 10065. E-mail: firstname.lastname@example.org. The Cancer Journal: 9/10 2018 - Volume 24 - Issue 5 - p 223-229 doi: 10.1097/PPO.0000000000000329 Buy Erratum Metrics Abstract Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma. Erratum In the September/October 2018 issue of , in the article by David J. Straus, MD, “Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity” (24:223-29), there was an error with Table 3. The table and its footnotes have been updated in the online version of the article: . DOI: 10.1097/PPO.0000000000000373 The Cancer Journal. 25(2):164, March/April 2019. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.